BBI Brickell Biotech Inc

Price (delayed)

$0.74

Market cap

$63.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.49

Enterprise value

$39.21M

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium ...

Highlights
The debt has plunged by 92% YoY and by 92% from the previous quarter
Brickell Biotech's EPS has soared by 90% YoY and by 36% from the previous quarter
Brickell Biotech's equity has decreased by 23% from the previous quarter but it has increased by 12% YoY
The company's revenue has shrunk by 90% YoY and by 58% QoQ
BBI's gross profit has shrunk by 90% YoY and by 58% QoQ

Key stats

What are the main financial stats of BBI
Market
Shares outstanding
85.92M
Market cap
$63.58M
Enterprise value
$39.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
151.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
116.34
Earnings
Revenue
$337,000
EBIT
-$31.78M
EBITDA
-$31.77M
Free cash flow
-$29.01M
Per share
EPS
-$0.49
Free cash flow per share
-$0.42
Book value per share
$0.33
Revenue per share
$0
TBVPS
$0.42
Balance sheet
Total assets
$29.07M
Total liabilities
$6.72M
Debt
$36,000
Equity
$22.35M
Working capital
$22.23M
Liquidity
Debt to equity
0
Current ratio
4.33
Quick ratio
3.65
Net debt/EBITDA
0.77
Margins
EBITDA margin
-9,427%
Gross margin
100%
Net margin
-9,449.6%
Operating margin
-9,593.8%
Efficiency
Return on assets
-99.5%
Return on equity
-130.9%
Return on invested capital
N/A
Return on capital employed
-141.9%
Return on sales
-9,430.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBI stock price

How has the Brickell Biotech stock price performed over time
Intraday
0.68%
1 week
4.23%
1 month
5.71%
1 year
-8.64%
YTD
-5.13%
QTD
-22.21%

Financial performance

How have Brickell Biotech's revenue and profit performed over time
Revenue
$337,000
Gross profit
$337,000
Operating income
-$32.33M
Net income
-$31.85M
Gross margin
100%
Net margin
-9,449.6%
BBI's operating margin has plunged by 194% from the previous quarter
The net margin has plunged by 190% from the previous quarter
The company's revenue has shrunk by 90% YoY and by 58% QoQ
BBI's gross profit has shrunk by 90% YoY and by 58% QoQ

Growth

What is Brickell Biotech's growth rate over time

Valuation

What is Brickell Biotech stock price valuation
P/E
N/A
P/B
2.22
P/S
151.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
116.34
Brickell Biotech's EPS has soared by 90% YoY and by 36% from the previous quarter
The price to book (P/B) is 121% higher than the 5-year quarterly average of 1.0 and 5% higher than the last 4 quarters average of 2.1
Brickell Biotech's equity has decreased by 23% from the previous quarter but it has increased by 12% YoY
BBI's P/S is 101% higher than its last 4 quarters average of 74.8
The company's revenue has shrunk by 90% YoY and by 58% QoQ

Efficiency

How efficient is Brickell Biotech business performance
Brickell Biotech's ROS has plunged by 190% from the previous quarter
The ROE has grown by 32% YoY but it has contracted by 20% from the previous quarter
The company's return on assets fell by 22% QoQ but it rose by 10% YoY

Dividends

What is BBI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBI.

Financial health

How did Brickell Biotech financials performed over time
BBI's total liabilities is down by 31% from the previous quarter and by 11% YoY
Brickell Biotech's total assets has decreased by 25% from the previous quarter but it has increased by 6% YoY
The debt is 100% less than the equity
Brickell Biotech's debt to equity has plunged by 100% from the previous quarter and by 100% YoY
The debt has plunged by 92% YoY and by 92% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.